8-K: Lantheus Holdings Reports Q1 2026 Results

Lantheus Holdings announced first quarter 2026 financial results, with worldwide revenue reaching $377.3 million, while also receiving FDA approvals for key products.

Summary

• Worldwide revenue for the first quarter of 2026 was $377.3 million, a 1.2% increase compared to the same period in 2025.
• GAAP fully diluted earnings per share (EPS) rose to $1.80, a significant increase from $1.02 in Q1 2025.
• Adjusted fully diluted EPS was $1.46, a slight decrease from $1.53 in Q1 2025.
• The company received FDA approval for PYLARIFY TruVuTM and tentative approval for Lutetium Lu 177 Dotatate (PNT2003).
• PYLARIFY sales were $240.9 million, down 6.5% year-over-year.
• DEFINITY sales increased by 6.8% to $84.6 million.
• Net cash provided by operating activities was $125.1 million, and free cash flow was $121.9 million.
• Cash and cash equivalents stood at $498.6 million as of March 31, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong GAAP EPS growth and key FDA approvals offset by a decline in adjusted EPS and a key product's sales.

Positives

• Worldwide revenue increased by 1.2% to $377.3 million in Q1 2026.
• GAAP fully diluted EPS saw a substantial increase of 76.5% to $1.80.
• FDA approval for PYLARIFY TruVuTM, a new formulation of their leading PSMA PET imaging agent.
• FDA tentative approval for PNT2003, potentially the first radioequivalent for gastroenteropancreatic neuroendocrine tumors.
• DEFINITY sales grew by 6.8% to $84.6 million.
• Strong free cash flow generation of $121.9 million.
• Increased cash and cash equivalents to $498.6 million, bolstered by the SPECT business divestiture.

Negatives

• PYLARIFY sales decreased by 6.5% to $240.9 million.
• Adjusted fully diluted EPS decreased by 4.6% to $1.46.
• Adjusted net income decreased by 12.5% to $95.8 million.
• Operating income decreased by 20.3% to $81.3 million.
• Adjusted operating income decreased by 10.5% to $129.1 million.

Risks

• Continued market expansion, penetration, and reimbursement for established products in a competitive environment.
• Ability to complete technology transfer for PYLARIFY TruVu and obtain necessary approvals and customer adoption.
• Availability of raw materials, key components, and equipment for product manufacturing.
• Ability to satisfy obligations under clinical development partnerships and license agreements.
• Successful integration of recent acquisitions, including potential unforeseen expenses and liabilities.
• Obtaining FDA approval and successful commercialization of LNTH-2501.
• Success in patent litigation and commercialization of PNT2003.
• Risks associated with clinical development, manufacturing, regulatory approval, and commercialization of new products and applications.

Future Outlook

The company reaffirmed its previously issued corporate guidance for full year 2026, expecting revenue between $1.4 billion and $1.45 billion, and adjusted fully diluted EPS between $5.00 and $5.25. The company is focused on sustaining leadership in PSMA PET, expanding its Alzheimer's imaging portfolio, and advancing its pipeline, with growth acceleration anticipated beginning in 2027.

Management Comments

• "Our first quarter results demonstrate disciplined execution across the business, with strong performance from PYLARIFY, Neuraceq, and DEFINITY, and continued progress against the priorities that underpin our long-term strategy."
• "For the remainder of 2026, we are focused on sustaining our leadership in PSMA PET as we prepare for the PYLARIFY TruVu conversion later this year, expanding our Alzheimers imaging portfolio, and advancing our prioritized pipeline."
• "At the same time, we will remain disciplined in our capital deployment, prioritizing radiodiagnostics while evaluating the best path to maximize value from our radiotherapeutic assets -- all as we lay the groundwork for growth acceleration beginning in 2027."

Industry Context

StockSavvy.ai notes that Lantheus Holdings' Q1 2026 results reflect the ongoing shift in the radiopharmaceutical market towards PET imaging agents, particularly in oncology and neurology. The FDA approvals for PYLARIFY TruVu and PNT2003 highlight the company's strategic focus on innovation and market leadership in these high-growth areas, while the decline in PYLARIFY sales suggests increasing competition or market saturation for that specific product.

Comparison to Industry Standards

• The 1.2% worldwide revenue growth for Lantheus in Q1 2026 is modest compared to some high-growth biotechnology firms, but aligns with expectations for established diagnostic imaging companies in a mature market segment.
• The 76.5% increase in GAAP diluted EPS is significantly influenced by non-operational items, such as the gain on sale of business, making direct comparison to peers based solely on this metric challenging without detailed reconciliation.
• The adjusted diluted EPS decline of 4.6% suggests that operational performance, excluding certain charges, faced headwinds, which is a common challenge for companies undergoing integration or product transitions.
• PYLARIFY's sales decline of 6.5% warrants comparison with competitors in the PSMA PET imaging space, such as those developing or marketing similar diagnostic agents, to understand market share dynamics.

Legal Proceedings

• The company is involved in legal proceedings related to PNT2003, which may impact its launch timing.

Stakeholder Impact

• Shareholders: Mixed impact due to increased GAAP EPS and FDA approvals, but decreased adjusted EPS and PYLARIFY sales may temper enthusiasm.
• Employees: Continued focus on strategic priorities and pipeline advancement may create opportunities, but financial performance pressures could influence compensation or resource allocation.
• Customers: Potential for new imaging capabilities with PYLARIFY TruVu and PNT2003, but launch timelines and adoption readiness are key.
• Suppliers: Continued demand for raw materials and manufacturing support for key products.

Next Steps

• Phased geographic launch of PYLARIFY TruVuTM to begin in the fourth quarter of 2026.
• Focus on sustaining leadership in PSMA PET.
• Expand Alzheimer's imaging portfolio.
• Advance prioritized pipeline.
• Evaluate the best path to maximize value from radiotherapeutic assets.
• Lay groundwork for growth acceleration beginning in 2027.
• Continue to monitor PDUFA date for LNTH2501 (June 29, 2026).

Key Dates

Recommendation

The company reported mixed results with strong GAAP EPS and significant FDA approvals, but a decline in adjusted EPS and a key product's sales. The reaffirmation of guidance and strategic focus on growth areas are positive, but the delays in PNT2003 and LNTH2501, along with competition in the PSMA PET market, warrant a cautious 'hold' stance pending further clarity on commercial execution and pipeline progression.

Keywords

Lantheus Holdings, PYLARIFY, PYLARIFY TruVu, PET imaging, radiopharmaceutical, financial results, FDA approval, Q1 2026